When companies hike prices on essentials like food, medicine, or medical devices, the financial rewards may be immediate—but ...

Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months– – Combination ...

Cash balance of $344.8 million as of September 30, 2025, together with net proceeds of ~$445 million from October 2025 equity offering, with expected runway into 2028 BEDFORD, Mass., Nov. 04, 2025 ...

Third quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million ---- December 20, 2025 PDUFA goal date ...

China’s dominance of the rare earth metals business—with a chokehold on Western militaries and key industries—has become a key geopolitical issue. Chinese companies make most of the parts that go into ...